Regen BioPharma Addresses Potential Impact of Recent Bristol-Myers Squibb's $2.3 Billion Acquisition Of IFM Therapeutics

Published: Aug 10, 2017

SAN DIEGO, August 10, 2017 /PRNewswire/ --

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) sees recent deal activity in the immune oncology space as an indication that big pharma continues to place significant bets on the ability of biotech companies to create the innovation they seek.

On August 3, 2017 Bristol Myers Squibb (BMS) announced that it had entered into an agreement to acquire IFM Therapeutics, a smaller biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

Back to news